OncLive TV

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the results of an exploratory analysis of the ongoing phase 3 CheckMate 227 trial in advanced non–small cell lung cancer.

Laura Spring, MD, discusses next steps of the phase 1/2 AMEERA-1 trial in estrogen receptor–positive, HER2-negative advanced breast cancer.

Saad Z. Usmani, MD, MBA, FACP, discusses emerging treatment strategies in late relapsed multiple myeloma.

William D. Tap, MD, discusses developing treatment opportunities in soft tissue sarcomas.

Jan Joseph Melenhorst, BSc, MS, PhD, discusses the persistence of CD4+ CAR T-cells in inducing remissions in patients with chronic lymphocytic leukemia.

Debra L. Richardson, MD, FACS, FACOG, discusses the rationale for the ongoing phase 3 UPNEXT trial in platinum-sensitive ovarian cancer.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, provide advice to female oncologists who are just starting out their careers.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss how and/or if any mentors they had during their careers helped them overcome gender-related challenges they experienced.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, share insight on how the corporate culture has changed in oncology practices with regard to gender inequality.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss some of the gender-related obstacles that they experienced throughout their careers as female oncologists.

Sam Klempner, MD, discusses the results of the ongoing phase 2a DisTinGuish trial in advanced gastroesophageal adenocarcinoma.

Manish A. Shah, MD, discusses the potential clinical implications of the ongoing phase 3 GLOW trial in Claudin 18.2-positive, HER2-negative gastric/gastroesophageal junction adenocarcinoma.

Laura Spring, MD, discusses the rationale for the ongoing phase 1/2 AMEERA-1 trial in estrogen receptor–positive, HER2-negative advanced breast cancer.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss their early experiences as female oncologists and some of the gender-related challenges they faced during their careers.

Alexander Babatunde Olawaiye, MD, discusses the investigation of balstilimab plus zalifrelimab in gynecologic cancers.

Ian E. Krop, MD, PhD, discusses the need to evaluate de-escalated treatment strategies in HER2-positive breast cancer.

Sara A. Hurvitz, MD, discusses progress made in 2021 with antibody-drug conjugates in HER2-positive breast cancer.

Ruta D. Rao, MD, discusses how the updated National Comprehensive Cancer Network guidelines have influenced treatment selection for patients with HER2-positive breast cancer.

Cortney Eakin, MD, discusses racial disparities and histology trends in uterine cancer.

Casey M. Cosgrove, MD, discusses utilizing biomarker-informed treatments in endometrial cancer.

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the qualities that make someone a great mentor for an oncology fellow.

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the process of selecting applicants to be accepted into an oncology fellowship.

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss whether it's still a possibility to be a general oncologist following an oncology fellowship.

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the compact style that comprises oncology fellowship training.

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, share advice in selecting a mentor during an oncology fellowship.

Shumei Kato, MD, discusses the characterization of BRAF mutations in oncology.

Sarah Lee, MD, MBA, discusses the association of microsatellite instability–high, mismatch repair deficiency, and tumor mutational burden–high features in endometrial cancer.

Amer Karam, MD, discusses determining whether to use debulking surgery after recurrence in ovarian cancer.

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, share their experiences as a fellowship director and an oncology fellow, respectively.

Yovanni Casablanca, MD, discusses the integration of pembrolizumab (Keytruda) into the paradigm of recurrent or metastatic cervical cancer.